Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Vöslau – page 22

865 clinical trials in Bad Vöslau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Vöslau at a glance
865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

865 trials in Bad Vöslau

Open in trial search

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Title: Long-term treatment study of oral decitabine and cedazuridine combination for patients with AML, MDS, CMML, or solid tumors who previously received ASTX727

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Study on Ruxolitinib and Methoxsalen for Patients with Steroid-Refractory Chronic Graft-versus-Host Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Methoxsalen
  • Sponsor:Medical Center - University Of Freiburg

Dermatomyositis+4

Recruiting

Study on Upadacitinib for Patients with Idiopathic Inflammatory Myopathies After Stopping IVIG

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:Medical University Of Vienna

Bladder cancer

Recruiting

Study on the Effectiveness of Gemcitabine Hydrochloride for Patients with Low Grade Bladder Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine Hydrochloride
  • Sponsor:Medical University Of Vienna

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Ruxolitinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study on Pancreatic Enzyme Replacement Therapy for Adults with Pancreatic Exocrine Insufficiency After Pancreatic Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pancreas Powder
  • Sponsor:MEDA Pharma GmbH & Co. KG

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Medica Scientia Innovation Research S.L.

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Vöslau

What the registry says about research in the country

01 Neuropathic Pain Studies

Investigating new treatment approaches for patients with diabetic polyneuropathy, focusing on innovative pain management solutions that could improve quality of life for those affected by chronic neuropathic conditions.

  • Diabetic Neuropathy Management
  • Chronic Pain Treatment
  • Add-on Therapy Evaluation

Research aims to enhance current treatment protocols for diabetes-related nerve pain.

02 Trauma-Related Neuropathy

Evaluating therapeutic options for patients experiencing post-operative and traumatic peripheral neuropathy, with a focus on developing effective pain management strategies for those affected by surgery or injury-related nerve damage.

  • Post-surgical Pain Management
  • Trauma-induced Neuropathy
  • Peripheral Nerve Pain

Studies explore innovative approaches to managing chronic pain resulting from surgical procedures and trauma.

03 Central Neuropathy Research

Examining treatment efficacy for central neuropathy of various origins, investigating novel therapeutic approaches for managing chronic pain associated with central nervous system conditions.

  • Central Nervous System Pain
  • Neurological Pain Management
  • Pain Relief Strategies

This research explores comprehensive treatment options for central nervous system-related pain conditions.

04 Chronic Back Pain Treatment

Investigating innovative therapies for patients suffering from chronic back pain, focusing on developing effective add-on treatments to enhance current pain management approaches.

  • Back Pain Management
  • Long-term Pain Relief
  • Therapeutic Advancement

Studies aim to improve treatment outcomes for individuals with persistent back pain conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.